Innovative immuno-therapy company welcomes a recognized leader in life sciences and therapeutics
AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, a privately-held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Cynthia (Cindy) Collins to the Board of Directors.
“We are very pleased that Cindy has joined Triumvira,” said President and CEO of Triumvira Immunologics, Paul Lammers. “Cindy brings extensive experience in leading and managing gene and cell therapy companies as well as strategic positioning, oncology drug development and product commercialization. We look forward to her contributions as we build our company and work to bring new treatments to patients in need.”
